diquafosol has been researched along with fluorescein in 14 studies
| Studies (diquafosol) | Trials (diquafosol) | Recent Studies (post-2010) (diquafosol) | Studies (fluorescein) | Trials (fluorescein) | Recent Studies (post-2010) (fluorescein) |
|---|---|---|---|---|---|
| 126 | 38 | 92 | 6,214 | 283 | 2,082 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Fujihara, T; Fujita, H; Murakami, T; Nakamura, M; Nakata, K | 1 |
| Bokosky, JE; Davitt, WF; Kellerman, DJ; LaVange, LM; Mills-Wilson, MC; Nichols, KK; Schaberg, AE; Tauber, J; Yerxa, BR | 1 |
| Igarashi, A; Ishii, R; Kamiya, K; Kobashi, H; Nakanishi, M; Sato, N; Shimizu, K | 1 |
| Ohashi, Y; Takamura, E; Tsubota, K; Watanabe, H | 1 |
| Ikeda, C; Koh, S; Maeda, N; Nishida, K; Takai, Y; Watanabe, H | 1 |
| Dogru, M; Higa, K; Ibrahim, OM; Kojima, T; Nagata, T; Satake, Y; Shimazaki, J; Shimazaki, S; Shimizu, T; Shirasawa, T; Tsubota, K | 1 |
| Hwang, HS; Kim, EC; Lee, WS; Sung, YM | 1 |
| Chen, X; Chua, WH; Chuan, JC; Gong, L; Gu, Y; Ma, Z; Shao, Y; Sun, X; Tang, L; Tong, L; Wang, Q; Xu, X; Yao, K; Yuan, H | 1 |
| Fukui, M; Kamoi, M; Kawakita, T; Mukai, S; Ogawa, Y; Saijo-Ban, Y; Simmura, S; Tsubota, K; Yaguchi, S; Yamane, M | 1 |
| Chen, WQ; Li, R; Wang, Y; Wu, D | 1 |
| Chung, JK; Lee, SJ; Park, DH; Seo, DR | 1 |
| Hanada, K; Kawahara, A; Utsunomiya, T; Yoshida, A | 1 |
| Choi, YH; Kim, DH; Kim, MK; Kim, Y; Paik, HJ | 1 |
| Hori, Y; Inai, M; Oka, K | 1 |
1 review(s) available for diquafosol and fluorescein
| Article | Year |
|---|---|
Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials.
Topics: Administration, Topical; Adult; Aged; Female; Fluorescein; Fluorescent Dyes; Humans; Keratoconjunctivitis Sicca; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Randomized Controlled Trials as Topic; Rose Bengal; Tears; Treatment Outcome; Uracil Nucleotides | 2015 |
7 trial(s) available for diquafosol and fluorescein
| Article | Year |
|---|---|
Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
Topics: Administration, Topical; Conjunctiva; Contrast Media; Cornea; Double-Blind Method; Dry Eye Syndromes; Female; Fluorescein; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Safety; Staining and Labeling; Tears; Treatment Outcome; Uracil Nucleotides | 2004 |
Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Hyaluronic Acid; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Rose Bengal; Tears; Uracil Nucleotides; Viscosupplements | 2012 |
A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients.
Topics: Cornea; Double-Blind Method; Dry Eye Syndromes; Fluorescein; Fluorescent Dyes; Humans; Hyaluronic Acid; Ophthalmic Solutions; Polyphosphates; Rose Bengal; Treatment Outcome; Uracil Nucleotides; Viscosupplements | 2012 |
Additive Effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops.
Topics: Aged; Drug Combinations; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Fluorophotometry; Humans; Hyaluronic Acid; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Preservatives, Pharmaceutical; Purinergic P2Y Receptor Agonists; Rose Bengal; Tears; Uracil Nucleotides; Viscosupplements | 2014 |
A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore.
Topics: Aged; Asian People; China; Dry Eye Syndromes; Fluorescein; Fluorescent Dyes; Humans; Hyaluronic Acid; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Rose Bengal; Singapore; Staining and Labeling; Tears; Treatment Outcome; Uracil Nucleotides; Viscosupplements | 2015 |
Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
Topics: Administration, Topical; Aged; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Hyaluronic Acid; Lens Implantation, Intraocular; Lissamine Green Dyes; Male; Middle Aged; Ophthalmic Solutions; Phacoemulsification; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Staining and Labeling; Surveys and Questionnaires; Tears; Uracil Nucleotides; Viscosupplements; Visual Acuity | 2016 |
Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.
Topics: Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Dry Eye Syndromes; Fluorescein; Humans; Ophthalmic Solutions; Polyphosphates; Tears; Treatment Outcome; Uracil Nucleotides | 2022 |
6 other study(ies) available for diquafosol and fluorescein
| Article | Year |
|---|---|
Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model.
Topics: Animals; Biological Transport; Cornea; Dry Eye Syndromes; Fluorescein; Fluorophotometry; Goblet Cells; Male; Membrane Glycoproteins; Ophthalmic Solutions; Permeability; Polyphosphates; Purinergic P2 Receptor Agonists; Rats; Rats, Sprague-Dawley; Tears; Uracil Nucleotides | 2001 |
Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye.
Topics: Aged; Conjunctiva; Cornea; Dry Eye Syndromes; Female; Fluorescein; Fluorometry; Follow-Up Studies; Humans; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Tears; Tomography, Optical Coherence; Treatment Outcome; Uracil Nucleotides | 2013 |
The effects of 3% diquafosol sodium application on the tear functions and ocular surface of the Cu,Zn-superoxide dismutase-1 (Sod1)-knockout mice.
Topics: Animals; Anterior Eye Segment; Conjunctiva; Epithelium, Corneal; Eye; Fluorescein; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mucin 5AC; Polyphosphates; Real-Time Polymerase Chain Reaction; RNA, Messenger; Rose Bengal; Superoxide Dismutase; Superoxide Dismutase-1; Tears; Time Factors; Uracil Nucleotides | 2014 |
Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.
Topics: Administration, Topical; Aged; Alanine; Drug Therapy, Combination; Dry Eye Syndromes; Enzyme Inhibitors; Female; Fluorescein; Fluorescent Dyes; Follow-Up Studies; Graft vs Host Disease; Humans; Middle Aged; Ophthalmic Solutions; Pemphigoid, Benign Mucous Membrane; Polyphosphates; Purinergic P2Y Receptor Agonists; Quinolones; Treatment Outcome; Uracil Nucleotides; Visual Acuity | 2015 |
Effects of Diquafosol Ophthalmic Solution on Quality of Life in Dry Eye Assessed Using the Dry Eye-Related Quality-of-Life Score Questionnaire: Effectiveness in Patients While Reading and Using Visual Display Terminals.
Topics: Activities of Daily Living; Computer Terminals; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Lubricant Eye Drops; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Purinergic P2Y Receptor Agonists; Quality of Life; Reading; Staining and Labeling; Surveys and Questionnaires; Tears; Tomography, Optical Coherence; Treatment Outcome; Uracil Nucleotides | 2017 |
Short-Term Effects of Ground-Level Ozone in Patients With Dry Eye Disease: A Prospective Clinical Study.
Topics: Adult; Aged; Cornea; Cross-Sectional Studies; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Oxidants, Photochemical; Ozone; Polyphosphates; Prospective Studies; Tears; Uracil Nucleotides | 2019 |